Kornimate/medical-research-clean huggingface dataset:
esketamine and propofol for children with autism spectrum disorder undergoing colonoscopy

Conditions: Autism Spectrum Disorder

Summary: the purpose of this study is to examine the dose-response relationship of esketamine in combination with propofol for children with autism spectrum disorder undering colonoscopy.

autistic children appear with significant frequency for medical services, lots of which requiring procedural sedation or anaesthesia. they have often been described as difficult to sedate or anesthetize due to a variety of asd symptoms. it is a challenging task to provide safe and effective sedation during the colonoscopic procedure in autism children. propofol sedation for endoscopic procedures is safe and acceptable for children, especially those who express significant anxiety. propofol-based sedation turned out to be the most effective dosage regimens, with effectiveness comparable to general anesthesia. the addition of certain dose ketamine to propofol may increase the effectiveness without creating more adverse events.

Eligibility criteria:
inclusion criteria: * （1) aged 2-12 years; * (2) diagnosed with asd by pediatric psychiatrists in accordance with the criteria in the fifth edition of diagnostic and statistical manual of mental disorders (dsm-v); * (3) evaluated as american society of anesthesiologists (asa) physical status i-ii; * (4) scheduled for colonic procedure. exclusion criteria: * (1) oral sedation (premedication) before intravenous catheter placement; * (2) any contraindication to study medications; * (3) other circumstances in which the investigator determined that a patient was not suitable for participation in the clinical trial.

Keywords: colonoscopy anaesthesia autism spectrum disorder propofol esketamine
transcutaneous electrical nerve stimulation (tens) and head and neck cancer pain (hnc) (tens & hnc)

Conditions: Head Cancer; Neck Cancer; Pain

Summary: the overall goal of this study is to examine the effect of a single dose of tens on mucositis pain and function secondary to head and neck radiation therapies. oral mucositis is an extremely debilitating, unpreventable condition (inflammation, ulcers, bleeding in the mouth, nose, and throat) that causes significant pain, functional impairment, and diminished quality of life. head and neck cancers pose specific challenges to effective pain management and past studies suggest the use of effective non-pharmacologic strategies such as tens may be particularly beneficial for avoiding sources of acute and chronic pain, thereby improving quality of life. the investigators hypothesize that a single dose of tens will decrease pain and improve function and quality of life in head and neck cancer patients. this project is particularly innovative because it is the first known study to examine the efficacy of tens, an established safe, inexpensive and easy-to-use non-pharmacologic pain management intervention, for treating acute oral mucositis pain. the investigators research translates bench (animal model) science to human subjects using an interdisciplinary approach to pain management. establishing whether tens is effective for reducing mucositis pain is a critical first step toward establishing an effective, non-pharmacologic pain relief intervention for mucositis.


Eligibility criteria:
inclusion criteria: * head and neck cancer diagnosis * oral mucositis diagnosis exclusion criteria: * tens use ≤ 5 years * pacemaker * pregnancy

Keywords: head and neck cancer oral cancer laryngeal cancer oropharyngeal cancer transcutaneous electrical nerve stimulation (tens) oral mucositis pain function tens functional pain non-pharamcologic quality of life
success of tocilizumab in ra patients with remission induction and sustained efficacy after discontinuation

Conditions: Rheumatoid Arthritis

Summary: the objective of this study is to investigate the efficacy and safety of the humanized anti-human il-6 receptor monoclonal antibody tocilizumab (tcz) either in monotherapy or in combination therapy with methotrexate (mtx) in patients with an inadequate response to treatment with mtx. furthermore, in patients who have been able to achieve control of disease activity via the above therapy, we investigate the possibility of stopping tcz and verify safety when tcz is restarted after disease recurrence.

in this study, we aim to prospectively and randomly evaluate efficacy for changes in clinical remission and joint destruction in ra patients in treatment with tcz monotherapy(switch) and in combination therapy with mtx(add-on), and also to investigate the best therapeutic approach to achieve discontinuation.

Eligibility criteria:
inclusion criteria: * diagnosed with ra in accordance with the 1987 classification criteria of acr * aged 20 to 75 years inclusive at enrolment (within 2 weeks before starting treatment with the investigational drug) * treated with mtx at ≥6 mg/week for at least 8 weeks immediately before enrolment * rheumatoid arthritis of duration ≤10 years * das28-esr ≥3.2 (within 2 weeks before starting treatment with the investigational drug) * having received and thoroughly understood an adequate explanation about participation in the study, patients who have personally and voluntarily provided written informed consent major exclusion criteria: * patients who were steinbrocker class iv. * patients who received leflunomide within 12 weeks, dmards other than mtx within 8 weeks , or tacrolimus within 4 weeks before the 1st tcz infusion. * patients who previously received biologic dmards including tcz.
pharmacological enhancement for nocturnal incontinence in orthotopic bladder substitute

Conditions: Incontinence; Urinary Incontinence; Urinary Bladder Cancer

Summary: in this randomised trial, we hypothesised that mebeverine could enhance nocturnal continenece of orthotopic bladder substitute (obs) patients by decreasing the frequency and reduce maximum amplitude of uninhibited contractions of obs ileum, and consequently it would increase the obs capacity


Eligibility criteria:
inclusion criteria: * nocturnal enuresis exclusion criteria: * daytime incontinence * orthotopic bladder substitute (obs) reconstruction surgery ≤2 years * chronic kidney disease * local tumor recurrence * adjuvant chemotherapy and/or radiotherapy * chronic retention requiring use of clean intermittent catheterization or indwelling urethral catheterization * suspected or known narrow-angle glaucoma * sensitivity to mebeverine.

Keywords: incontinence
focal muscle vibrations in acute stroke

Conditions: Acute Stroke

Summary: a prospective, randomized, double-blind, sham-controlled trial designed to evaluate the effects of repeated muscle vibration (rmv) on motor recovery in acute stroke patients treated within 72 hours of symptom onset

after enrollment (t0), patients are randomly assigned to either the vibration group (vg) or the control group (cg). patients in the vg will receive rmv treatment, while those in the cg receive sham treatment. both interventions are administered on the 1st, 2nd, and 3rd days post-enrollment. physiokinesitherapy (pt) and occupational therapy (ot) are provided daily to all patients, starting immediately after the t0 clinical evaluation. patients are re-evaluated after 4 ± 1 days (t-1), marking the end of the treatment period. upon admission, demographic details and medical histories of all participants are recorded. each patient undergoes clinical evaluations at all time points by an experienced investigator blinded to group allocation and distinct from the recruiting personnel. the clinical assessment includes stroke severity evaluation using the nih stroke scale, motor and functional limb abilities using the fugl-meyer scale, safe score, and motricity index. additionally, bioimpedance analysis of muscle mass and phase angle in the impaired upper limb is performed using the bwa device. all participants follow a standardized daily rehabilitation program. physical therapists, blinded to treatment allocation, are instructed on the duration, frequency, and content of therapy to ensure consistency across groups. low-amplitude rmv (frequency: 100 hz; amplitude: 1-2 mm) is applied to the flexor carpi radialis and biceps brachii for upper limb treatment, using a commercial device (vibramoov physio, technoconcept, mane, france). the rmv sessions are conducted over three consecutive days by two trained physiotherapists, with each daily session comprising three 10-minute treatments (per treated limb) interspersed with 1-minute breaks. during the rmv sessions, participants are instructed to perform voluntary isometric contractions of the treated muscle. in contrast, cg participants undergo sham rmv, where the vibrator is positioned near the tendon but without vibration.

Eligibility criteria:
inclusion criteria: 1. voluntary patients in the acute phase of a sylvian ischemic stroke (from day 1 to day 7 post-stroke) 2. estimated hospital stay expected to exceed 7 days 3. age ≥ 18 years 4. able to understand and follow evaluation instructions 5. provided informed consent 6. affiliated with a social security scheme 7. safe score between 4 and 7 on the affected side exclusion criteria: 1. individuals under guardianship or curatorship 2. individuals deprived of liberty 3. individuals under legal protection (safeguard of justice) 4. other neurological or rheumatological conditions limiting mobility 5. drowsiness (related to stroke or medication) 6. pregnant or breastfeeding women

Keywords: acute stroke repetitive tendinous vibrations motor recovery non pharmacological therapy bedside intervention
clinical trial : trocc (quick oral treatment of cluster epileptic seizures)

Conditions: Epilepsy; Drug Resistant

Summary: this is a double blind, placebo controlled, add-on clinical trial, of levetiracetam efficacy and safety, in epilepsy cluster seizure. efficacy is evaluated in the range of 2 to 24 hours after taking the tablet. if the patient has a seizure during this interval, he is considered as a non-respondent patient.

seizure clustering has been defined as a series of unusual frequency of seizures with return to baseline between events. the most common definition of cluster seizure is three seizures per 24 hours. the usual treatment of cluster seizure is benzodiazepin. this is recognized efficient therapy but has many side effects. thus it is important to develop as an new therapeutic to improve patient care. levetiracetam is an antiepileptic drug used in addition to other antiepileptic drugs with less side effects than benzodiazepin. the aim of this study is to evaluate the effectiveness and safety of levetiracetam in epilepsy cluster seizure. this is a double blind, placebo controlled, add-on clinical trial with two phases : phase 1 : double blind phase during 24 hours (h0 to h24). after consent signature and randomization, the patient takes two tablets of levetiracetam or placebo. if the patient has a seizure between h3 and h24, he is considered as a non-respondent patient. if there is a risk of rapid evolution to an statue epilepticus, the investigator can break the blind and adapt the patient treatment accordingly. phase 2 : this is an open phase after h24. this phase consists of breaking the blind with free adaption of the therapy by the investigator, and patients follow-up during 1 month. the randomization is stratify by center. the size of randomization blocks is random because of the systematic breaking blind after 24 hours.

Eligibility criteria:
inclusion criteria: * age from 18 to 65 * drug resistant epilepsy, partial seizure * epilepsy diagnosed for more than 2 years * epilepsy treated for more than 1 year with no change of treatment in the month before the enrolment * onset of cluster seizure in the 24 hours before enrolment * for women : effective contraception * affiliation to the french social security exclusion criteria: * inability to tolerate levetiracetam, likely poor compliance * patient taking antiepileptic treatment (benzodiazepine) in addition to current treatment during the last 48h00. * patient taking 1g/day of levetiracetam with creatinin clearance \< 50ml/min * patient taking 2g/day of levetiracetam with creatinin clearance \< 80ml/min * patient taking more than 2g/day of levetiracetam * hepatic or cardiovascular pathology * progressive psychiatric pathology * degenerative neurologic disease * cluster seizure due to an acute symptomatic reason * disorder of consciousness * suspicion of status epilepticus or rapid evolution to status epilepticus * suspicion of psychogenic nonepileptic seizure * pregnant woman or nursing woman * suicidal thoughts * incapacity to give consent, minor patient

Keywords: cluster seizure seizure clustering repetitive seizure drug resistant epilepsy levetiracetam keppra
persistent cervical hpv infection with clearance and vaginal microbiota

Conditions: HPV-Related Squamous Cell Carcinoma

Summary: since other genital infections enhance hiv susceptibility by inducing inflammation, the investigators study the relationship between the vaginal microbiota composition and the persistence infection and clearance of hpv infection.

persistent infection with oncogenic human papillomavirus (hpv) is necessary but not sufficient for the development of cervical cancer. additional factors correlated with hpv persistence include immunodeficiency caused by hiv, smoking, use of oral contraceptives and, more recently reported, vaginal dysbiosis. in a state of dysbiosis, there is a marked reduction of lactobacillus and a high diversity of bacteria, with increased abundance of anaerobic bacterial species. high-risk hpv cervical infections are common in young, sexually active women. most of these infections are transient and do not cause clinical symptoms. after 12-30 months of hpv infection, 70-90% of patients can be cleared naturally, but there are still a small number of patients with high-risk hpv infection can not be eliminated by itself and continue to infect, and can develop into cervical intraepithelial neoplasia, eventually progressing to invasive cervical cancer. persistent infection of high-risk hpv is a necessary condition for the occurrence of cervical cancer and precancerous lesions. early blocking of persistent infection of high-risk hpv and timely treatment of cervical precancerous lesions are of great significance in preventing the occurrence of cervical cancer. this project intends to study the relationship between vaginal microbial composition and persistent hpv infection, and determine the related strains and their molecular mechanisms, so as to provide new ideas and basis for its treatment.

Eligibility criteria:
inclusion criteria: * those are aged 20 to 45 years old, have had vaginal intercourse more than 3 years, and aren't in menstrual, pregnancy or puerperium period. exclusion criteria: * those have no vaginal intercourse, and can't cooperate the examiner. women who are hiv or hepatitis b/c positive, have autoimmune disorders and systemic disease (like diabetes mellitus, hormone treatment diseases, severe liver and kidney dysfunction), or have severe mental illness and malignant tumors are also excluded. at the same time, all the participants should meet the following requirements: no vagina douching within last 2 days, no vaginal intercourse within last 3 days, no systemic application of antifungal agents or antibiotics or pessaries within last 14 days of sampling.
changes in cancer-related cytokines after participation in a physical activity behavior change intervention (cick study)

Conditions: Breast Cancer

Summary: it is important to confirm health benefits experienced by breast cancer survivors after participation in a physical activity behavior change intervention. one such potential benefit is a reduction in harmful inflammation that might lead to increased symptoms or cancer risk. because little is known about how physical activity behavior change interventions influence inflammation in breast cancer survivors, the investigators study will measure inflammation with blood markers known as cytokines among breast cancer survivors before and after a physical activity intervention. such information has the potential to lead to improved physical functioning, reduction in bothersome symptoms (e.g., fatigue), and reduced cancer risk in breast cancer survivors.


Eligibility criteria:
inclusion criteria: * female breast cancer patients between the ages of 18 and 70 years of age with a diagnosis of stage i, ii, or iiia breast cancer who are not currently receiving (and do not plan to receive during the study duration) chemotherapy or radiation therapy. the participant may be taking longer term therapies such as aromatase inhibitors, estrogen receptor modulators, etc. * if the patient has undergone a surgical procedure, must be at least 8 weeks post-procedure. * english speaking. * medical clearance for participation provided by primary care physician or oncologist. exclusion criteria: * diagnosis of dementia or organic brain syndrome. * medical, psychological, or social characteristic that would interfere with ability to fully participate in program activities and assessments (e.g., psychosis, schizophrenia, etc.). * contraindication to participation in a regular physical activity program. * metastatic or recurrent disease * inability to ambulate * engaged in ≥ 60 minutes of vigorous physical activity or ≥ 150 minutes of moderate plus vigorous activity per week during the past month. * anticipates undergoing elective surgery during the duration of the intervention which would interfere with intervention participation (e.g., breast reconstructive surgery). * participant does not live or work within 50 miles of the study site.

Keywords: breast cancer exercise biomarkers
validation of a home-screening test for lactose intolerance

Conditions: Lactose Intolerance

Summary: the hypothesis underlying this study is that whilst there is no home-screening test for lactose intolerance, this test would have significant value as lactose tolerance tests and breath hydrogen tests are expensive and time consuming. therefore, it would be highly beneficial to validate a simple home-screening test. this study will validate a simple home-screening test that uses lactose and not milk.


Eligibility criteria:
inclusion criteria: * diagnosed lactose intolerance as demonstrated by a lactose tolerance test * diagnosed as not having lactose intolerance as demonstrated by a lactose tolerance test exclusion criteria: * pregnant * breastfeeding * unwillingness to comply with study outline

Keywords: lactose intolerance lactose home-screening test validate
non invasive optical imaging of wbc count

Conditions: Hematologic Malignancy

Summary: this research study is looking at a small device that measures white blood cell (wbc) counts by being placed against the finger nail for participants who are undergoing stem cell transplantation at massachusetts general hospital or have a hematologic malignancy and are being seen as an outpatient.

the objective of this study is to obtain data that would support the use of a method to obtain wbc counts from images of small blood vessels called capillaries. these would be obtained by pressing a small device on the surface of participants' finger nails to look through the nail. these images will be obtained using a portable microscope called the dino-lite digital microscope. having a non-invasive way to quickly measure wbc counts could be useful for a variety of healthcare applications.

Eligibility criteria:
inclusion criteria: * patients with lymphoid malignancies or plasma cell dyscrasias who are admitted to the massachusetts general hospital to undergo autologous stem cell transplantation or are seen in the outpatient clinic * age ≥ 18 years * ability to understand and the willingness to sign a written informed consent document. * patients must have wbc ≥ 3000 / µl and anc ≥ 1500 / µl at admission or their last clinical visit to be enrolled. exclusion criteria: * history of allergic reactions attributed to compounds of similar chemical or biologic composition of baby oil. * myelodysplasia * skin phototype \< 4 in the fitzpatrick scale.

Keywords: hematologic malignancy
remote patient monitoring and health coaching vs. usual care for the treatment of hypertension

Conditions: Hypertension

Summary: high blood pressure, also known as hypertension, affects nearly half of all americans and increases the risk for heart disease and stroke. only about half of people with high blood pressure have it under control. new methods to control blood pressure are needed to reduce heart attack and stroke rates. the purpose of this study is to test whether a digital program that includes personalized health coaching and remote patient monitoring with a connected blood pressure cuff, all delivered on a smartphone or website, can improve blood pressure control compared with usual care among patients with high blood pressure.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of hypertension * 18+ years of age * english-speaking * receives primary care at stanford primary care exclusion criteria: * \<18 years of age * primary language not english * active or prior enrollment in omada program
home-based executive function training intervention for attention-deficit/ hyperactivity disorder-prone children

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)

Summary: this study aims to investigate the effectiveness of a home-based executive function training intervention on children's adhd symptoms, executive function and parents' parenting stress.


Eligibility criteria:
inclusion criteria: * 1.snap-iv scale, inattention or hyperactivity-impulsivity scale score \> 1.2 * 2.parents who could understand or lacking of access to computers and the internet * 3.parents can commit to ensuring full participation and complete the training and test evaluations in full compliance with the researcher's requirements * 4.children and their parents consent to the study exclusion criteria: * 1.children or parents with severe organic encephalopathy and other severe mental disorders * 2.parents or children are receiving adhd-related behavioral treatment * 3.parents or children who dropped out before the study started or in the middle of the study

Keywords: attention deficit hyperactivity disorder (adhd) executive function training
diabetes, falls, and fractures

Conditions: Diabetic Peripheral Neuropathy; Diabetes; Balance; Distorted; Vestibular Neuropathy; Muscle Weakness; Sarcopenia; Autonomic Neuropathy, Diabetic; Small Fiber Neuropathy

Summary: comparing severity of diabetic peripheral neuropathy (small and large fibers including autonomic neuroapthy) to postural control and vestibular measurements


Eligibility criteria:
inclusion criteria: 1. men and women with minimum 40 years of age and maximum 70 years of age. 2. diagnosis of t1d or t2d 3. diagnosis of diabetes with at least one year prior to inclusion of the study 4. signed the informed consent. exclusion criteria: 1. severe decreased liver function (alanin amino-transaminase (alat)\>250u/l, gammaglutamyltransferase (ggt)\>150u/l) 2. moderate to severe kidney dysfunction, estimated glomerular filtration rate (egfr) \<15mmol/l/1,73m2 3. pregnancy or breast feeding 4. active malignancy or terminal ill. 5. current or previous alcohol- or drug abuse 8. not being able to understand danish written and/or verbally 9. terms according to investigators judgement that makes subjects unsuitable to participate including lack of understanding or reduced physical ability. 10. participating in other clinical studies 11. maximum of 10 hours of weekly exercise.

Keywords: diabetes balance vestibular neuropathy muscle weakness autonomic neuropathy small fiber neuropathy postural control